IP Library Granted Patent US 8,969,330
Granted Patent B2
US 8,969,330 · App. 13/761,889 · Granted Mar 3, 2015

Steroids as agonists for FXR

Inventor: Roberto Pellicciari (Perugia, IT)
Assignee: Intercept Pharmaceuticals, Inc.
C07J41/0055C07J9/00C07J9/005C07J43/00Y10S514/893
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,969,330
App. No.
13/761,889
Granted
Mar 3, 2015
Kind
B2
Abstract

The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.

Claims (13)

1. A process for preparing a compound of formula I:

or a pharmaceutically acceptable salt or amino acid conjugate thereof, comprising:

a) reacting 3α-hydroxy-7-keto-5β-cholan-24-oic acid with 3,4-dihydropyrane to prepare 3α-tetrahydropyranyloxy-7-keto-5β-cholan-24-oic acid;

b) reacting 3α-tetrahydropyranyloxy-7-keto-5β-cholan-24-oic acid with an alkyl bromide of the formula R—Br, wherein R is ethyl, to prepare a compound of formula II:

c) reacting the compound of formula II with sodium borohydride to prepare a compound of formula III:

d) reacting the compound of formula II with sodium hydroxide to prepare the compound of formula I.

2. A method of increasing flow of bile acids from the liver to the intestine in a subject suffering from a cholestatic liver disease, comprising administering to the subject a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt or amino acid conjugate thereof.

3. The method of claim 2 , wherein the compound is a glycine conjugate of the compound of formula I.

4. The method of claim 2 , wherein the compound is a taurine conjugate of the compound of formula I.

5. The method of claim 2 , wherein the compound is a pharmaceutically acceptable salt of the compound of formula I.

6. The method of claim 2 , wherein the subject is a mammal.

7. The method of claim 6 , wherein the mammal is a human.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0856 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2013
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 029962/0282 →
Continuity (6)
Continuation 13288558 · Nov 3, 2011
Continuation 12547147 · Aug 25, 2009
Continuation 11602307 · Nov 21, 2006
Continuation 10471549
Provisional Application 60274959 · Mar 12, 2001
Related Publication 20140024631A1 · Jan 23, 2014